Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


PP-UNP-USA-5796

Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.

 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796

Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading

PP-UNP-USA-5796

Leave ordering?

Changes you have made will not be saved.

Visit Pfizer Medical

This site is intended for U.S. healthcare professionals.

Search

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Change IndicationLoading
Search
Menu
Close
CIDPAbout PANZYGAEfficacyEfficacyTrial designEfficacySafety and tolerabilityDosingPatient profilesMaterials and supportMaterials and supportEventsMaterialsVideosSupport homePANZYGA Co-Pay ProgramsPfizer IGuideFAQsRequest a representativeIg Companion
Prescribing InformationIndicationsPatient Site

FAQs

Frequently asked questions about PANZYGAWhat are the most common adverse reactions (ARs) seen with PANZYGA?
CIDP in adults1
The most common ARs reported in greater than 5% of subjects during a clinical trial were headache (15%; 21 of 142), fever (14%; 20 of 142), dermatitis (10%; 14 of 142), and blood pressure increase (8%; 11 of 142). ARs were similar across treatment arms except for headache, for which there was an evident dose effect. The evident dose-related effect for the 2g/kg dose was 24%.

PI in patients aged 2 years and older1
The most common ARs observed at a rate of more than 5% in patients in clinical studies were headache (22%; 11 of 51), abdominal pain (14%; 7 of 51), fever (14%; 7 of 51), nausea (10%; 5 of 51), sinusitis (8%; 4 of 51), fatigue (6%; 3 of 51), and bronchitis (6%; 3 of 51).

cITP in adults1
The most common ARs observed at a rate of more than 5% in patients in a clinical trial were headache (50%; 20 of 40), fever (23%; 9 of 40), nausea (18%; 7 of 40), vomiting (10%; 4 of 40), dizziness (10%; 4 of 40), and anemia (10%; 4 of 40).

One of 40 patients with cITP treated with PANZYGA developed aseptic meningitis on day 2 of the infusion. This patient was managed with antibiotics and supportive care with recovery.
Is premedication required with PANZYGA infusions?
CIDP study1,2
During the CIDP study, 11 patients (8%) received premedication. The use of premedication was only allowed under certain conditions. Patients who experienced 2 consecutive infusion-related adverse events that were likely to be prevented by premedication were permitted to receive antipyretics, antihistamines, or antiemetic drugs.



PI studies3
Only 2 patients received premedication (4%) for 3 infusions (0.4%) in the PI clinical study.
No patient received premedication in the PI extension study.



cITP study1

Premedication was not allowed in the cITP study.
What vial sizes are available for PANZYGA?
PANZYGA is available in 5 vial sizes to meet individual patient needs: 25 mL (2.5 g), 50 mL (5 g), 100 mL (10 g), 200 mL (20 g), and 300 mL (30 g). PANZYGA is supplied in single-use bottles.1
Where can I get more information about PANZYGA?
Please contact your Pfizer sales representative.
Tel: 1-844-646-4398

Or click here to request a representative.

Medical Information
[email protected]
Tel: 1-888-429-4535
What if my patients cannot tolerate their PANZYGA infusion and/or infusion rate?
Patients should be carefully monitored throughout the infusion, and the infusion rate should be adjusted if adverse drug reactions related to the rate of infusion occur. The package insert for PANZYGA recommends using an appropriate dose the patient can tolerate.1 Click on the links to get help with PANZYGA dosing and infusion rates for CIDP, PI, and cITP.
How is PANZYGA stored?
Store PANZYGA for up to 36 months at 36 °F to 46 °F (2 °C to 8 °C) from the date of manufacture. Within its shelf life, the product may be stored at room temperature (≤77 °F or 25 °C) for up to 12 months. After storage at ≤77 °F (25 °C), either use immediately or discard the product. Do not use after expiration date. Do not freeze. Do not use frozen product.1
When and how should the infusion line be flushed?
After administration, the infusion line may be flushed with either normal saline or 5% dextrose in water.1
Can PANZYGA be simultaneously infused with another intravenous preparation in the same infusion set?
Do not administer PANZYGA simultaneously with another intravenous preparation in the same infusion set, including immune globulin products from another manufacturer.1
Which infusion pumps have been used to administer PANZYGA?
In clinical trials, the following 2 pumps were used: Perfusor® and Infusomat®.
What is the IgA content level in PANZYGA?
The IgA content level of PANZYGA is 100 µg/mL. PANZYGA is contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.1
What stabilizer does PANZYGA use?
PANZYGA is stabilized with glycine and does not contain preservatives or sucrose.1 Click here to learn more.
References:Panzyga. Prescribing Information. Octapharma USA Inc.; 2025. Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): study design and protocol. J Peripher Nerv Syst. 2018;23:108-114.  Borte M, Melamed IR, Pulka G, et al. Efficacy and safety of human intravenous immunoglobulin 10% (Panzyga®) in patients with primary immunodeficiency diseases: a two-stage, multicenter, prospective, open-label study. J Clin Immunol. 2017;37(6):603-612.Support

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PAN-USA-1048
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367

INDICATIONS AND USAGE
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.
IMPORTANT SAFETY INFORMATIONWARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
Contraindications
PANZYGA is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
Warnings and Precautions
Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.
Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving PANZYGA. 
Aseptic meningitis syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion.Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).Monitor blood pressure prior to, during, and following PANZYGA infusion.Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload.PANZYGA is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent.Adverse Reactions
PI – The most common adverse reactions (>5% study subjects) were headache, nausea, fever, fatigue, and abdominal pain.cITP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, nausea, vomiting, dizziness, and anemia.CIDP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, dermatitis, and blood pressure increase.The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for PANZYGA. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. PANZYGA® is a registered trademark of Octapharma AG. Please click here for full Prescribing Information, including BOXED WARNING.

Manufactured by Octapharma Pharmazeutika Produktionsges m.b.H.
Distributed by Pfizer Labs, Division of Pfizer Inc.
INDICATIONS
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.